StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)

Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –

Exelixis revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Exelixis's revenue for the twelve months ending Oct 2, 2026 was $2.50B, up 9.1% year over year. For fiscal 2025 it was $2.32B, up 7.0% from the year before. Over ten years it grew 51.2% a year on average. The highest annual figure on record is $2.32B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Jan 2, 2026$2.32B+7.0%
FY2024Jan 3, 2025$2.17B+18.5%
FY2023Dec 29, 2023$1.83B+13.6%
FY2022Dec 30, 2022$1.61B+12.3%
FY2021Dec 31, 2021$1.43B+45.3%
FY2020Jan 1, 2021$987.54M+2.0%
FY2019Jan 3, 2020$967.78M+13.3%
FY2018Dec 28, 2018$853.83M+88.7%
FY2017Dec 29, 2017$452.48M+136.3%
FY2016Dec 31, 2016$191.45M+415.0%
FY2015Dec 31, 2015$37.17M+48.0%
FY2014Dec 31, 2014$25.11M-19.9%
FY2013Dec 31, 2013$31.34M-34.0%
FY2012Dec 31, 2012$47.45M-83.6%
FY2011Dec 31, 2011$289.64M+56.5%
FY2010Dec 31, 2010$185.05M+21.9%
FY2009Dec 31, 2009$151.76M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$658.70M+10.2%
Q2 FY2026Jul 3, 2026$628.69M+10.6%
Q1 FY2026Apr 3, 2026$610.81M+10.0%
Q4 FY2025Jan 2, 2026$598.66M+5.6%
Q3 FY2025Oct 3, 2025$597.76M+10.8%
Q2 FY2025Jul 4, 2025$568.26M-10.8%
Q1 FY2025Apr 4, 2025$555.45M+30.6%
Q4 FY2024Jan 3, 2025$566.76M+18.2%
Q3 FY2024Sep 27, 2024$539.54M+14.3%
Q2 FY2024Jun 28, 2024$637.18M+35.6%
Q1 FY2024Mar 29, 2024$425.23M+4.0%
Q4 FY2023Dec 29, 2023$479.65M+13.1%
Q3 FY2023Sep 29, 2023$471.92M+14.6%
Q2 FY2023Jun 30, 2023$469.85M+12.0%
Q1 FY2023Mar 31, 2023$408.79M+14.8%
Q4 FY2022Dec 30, 2022$423.92M-6.0%
Q3 FY2022Sep 30, 2022$411.74M+25.4%
Q2 FY2022Jul 1, 2022$419.43M+8.9%
Q1 FY2022Apr 1, 2022$355.98M+31.7%
Q4 FY2021Dec 31, 2021$451.14M+67.1%
Q3 FY2021Oct 1, 2021$328.42M+42.1%
Q2 FY2021Jul 2, 2021$385.18M+48.4%
Q1 FY2021Apr 2, 2021$270.23M+19.1%
Q4 FY2020Jan 1, 2021$270.05M+12.4%
Q3 FY2020Oct 2, 2020$231.09M-14.9%
Q2 FY2020Jul 3, 2020$259.48M+8.0%
Q1 FY2020Apr 3, 2020$226.92M+5.3%
Q4 FY2019Jan 3, 2020$240.31M+5.1%
Q3 FY2019Sep 27, 2019$271.70M+20.5%
Q2 FY2019Jun 28, 2019$240.28M+29.1%
Q1 FY2019Mar 29, 2019$215.49M+0.8%
Q4 FY2018Dec 28, 2018$228.60M+90.4%
Q3 FY2018Sep 28, 2018$225.40M+47.8%
Q2 FY2018Jun 29, 2018$186.11M+88.0%
Q1 FY2018Mar 30, 2018$213.72M+164.2%
Q4 FY2017Dec 29, 2017$120.07M+54.8%
Q3 FY2017Sep 30, 2017$152.51M–
Q2 FY2017Jun 30, 2017$99.01M–
Q1 FY2017Mar 31, 2017$80.89M–
Q4 FY2016Dec 31, 2016$77.58M–

More Exelixis figures

See a number that looks wrong?